Literature DB >> 12153472

Measuring nicotinic receptors with characteristics of alpha4beta2, alpha3beta2 and alpha3beta4 subtypes in rat tissues by autoradiography.

David C Perry1, Yingxian Xiao, Henry N Nguyen, John L Musachio, Martha I Dávila-García, Kenneth J Kellar.   

Abstract

Comparison of [125I]epibatidine and 5-[125I]iodo-3-(2-azetidinylmethoxy)pyridine ([125I]A-85380) autoradiography showed evidence for nicotinic receptor heterogeneity. To identify the receptor subtypes, we performed [125I]epibatidine autoradiography in the presence of cytisine or A-85380. By comparing these results with binding data from human embryonic kidney (HEK) 293 cells stably transfected with different combinations of rat nicotinic receptor subunits, we were able to quantify three distinct populations of [125I]epibatidine binding sites with characteristics of alpha4beta2, alpha3beta2 and alpha3beta4 receptors. Although the predominant subtype in rat brain was alpha4beta2, non-alpha4beta2 binding sites were prominent in many regions. In the habenulo-peduncular system, cerebellum, substantia gelatinosa, and many medullary nuclei, alpha3beta4-like binding accounted for more than 40% of [125I]epibatidine binding, and nearly all binding in superior cervical ganglion and pineal gland. Other regions enriched in alpha3beta4-like binding included locus ceruleus, dorsal tegmentum, subiculum and anteroventral thalamic nucleus. Regions enriched in alpha3beta2-like binding included the habenulo-peduncular system, many visual system structures, certain geniculate nuclei, and dopaminergic regions. The combination of autoradiography using a broad spectrum radioligand in the presence of selective competitors, and data from binding to defined receptor subtypes in expression systems, allowed us to quantify the relative populations of these three subtypes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12153472     DOI: 10.1046/j.1471-4159.2002.00951.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  107 in total

1.  AT-1001: a high affinity and selective α3β4 nicotinic acetylcholine receptor antagonist blocks nicotine self-administration in rats.

Authors:  Lawrence Toll; Nurulain T Zaveri; Willma E Polgar; Faming Jiang; Taline V Khroyan; Wei Zhou; Xinmin Simon Xie; Gregory B Stauber; Matthew R Costello; Frances M Leslie
Journal:  Neuropsychopharmacology       Date:  2012-01-25       Impact factor: 7.853

Review 2.  Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia.

Authors:  Carrie K Jones; Nellie Byun; Michael Bubser
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

3.  Novel α3β4 nicotinic acetylcholine receptor-selective ligands. Discovery, structure-activity studies, and pharmacological evaluation.

Authors:  Nurulain Zaveri; Faming Jiang; Cris Olsen; Willma Polgar; Lawrence Toll
Journal:  J Med Chem       Date:  2010-10-27       Impact factor: 7.446

Review 4.  From smoking to lung cancer: the CHRNA5/A3/B4 connection.

Authors:  M R D Improgo; M D Scofield; A R Tapper; P D Gardner
Journal:  Oncogene       Date:  2010-06-28       Impact factor: 9.867

5.  Regulation of α4β2α5 nicotinic acetylcholinergic receptors in rat cerebral cortex in early and late adolescence: Sex differences in response to chronic nicotine.

Authors:  Bethany G Hoegberg; Ermelinda Lomazzo; Norman H Lee; David C Perry
Journal:  Neuropharmacology       Date:  2015-08-10       Impact factor: 5.250

Review 6.  Nicotinic modulation of hippocampal cell signaling and associated effects on learning and memory.

Authors:  Munir Gunes Kutlu; Thomas J Gould
Journal:  Physiol Behav       Date:  2015-12-11

7.  Coantagonism of glutamate receptors and nicotinic acetylcholinergic receptors disrupts fear conditioning and latent inhibition of fear conditioning.

Authors:  Thomas J Gould; Michael C Lewis
Journal:  Learn Mem       Date:  2005 Jul-Aug       Impact factor: 2.460

8.  A randomized, double-blind, placebo-controlled phase 2 study of α4β2 agonist ABT-894 in adults with ADHD.

Authors:  Earle E Bain; Weining Robieson; Yili Pritchett; Tushar Garimella; Walid Abi-Saab; George Apostol; James J McGough; Mario D Saltarelli
Journal:  Neuropsychopharmacology       Date:  2012-10-03       Impact factor: 7.853

9.  [¹²⁵I]AT-1012, a new high affinity radioligand for the α3β4 nicotinic acetylcholine receptors.

Authors:  Jinhua Wu; David C Perry; James E Bupp; Faming Jiang; Willma E Polgar; Lawrence Toll; Nurulain T Zaveri
Journal:  Neuropharmacology       Date:  2013-10-03       Impact factor: 5.250

10.  Acute nicotine reduces brain arachidonic acid signaling in unanesthetized rats.

Authors:  Lisa Chang; Stanley I Rapoport; Henry N Nguyen; Dede Greenstein; Mei Chen; Mireille Basselin
Journal:  J Cereb Blood Flow Metab       Date:  2009-01-14       Impact factor: 6.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.